BEIJING, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology
International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"),
a leading developer, producer and distributor of nutrients for plants and
animals, located in the People's Republic of China, today announced that
the Company will present at the upcoming Roth Capital "China Comes to
Vegas" conference held on November 19-21, 2008 at the Wynn Hotel in Las
The Roth Capital "China Comes to Vegas" conference is a three day event dedicated to US listed companies with operations in China. There will be executives from more than 70 companies at the conference. Details of Yongye's presentation are:
Date: Friday, November 21, 2008
Time: 01:00 P.M. Pacific Time
Presenters: Mr. Zishen Wu, Chairman and CEO;
Mr. Larry Gilmore, Vice President of Corporate Strategy
Venue: Palmer 1
Las Vegas, Nevada
The Company will be available to meet with analysts and investors during the conference. Participation in the Roth "China Comes to Vegas" conference is by invitation only. For more information about the conference, please visit http://www.roth.com/ or E-mail firstname.lastname@example.org .
About Yongye Biotechnology International, Inc.
Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the research and development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.
Safe Harbor Statement
This press release contains certain statements that may include
"forward looking statements." All statements other than statements of
historical fact included herein are "forward-looking statements." These
forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," "expects" or similar
expressions, involving known and unknown risks and uncertainties. Although
the Company believes that the expectations reflected in these
forward-looking statements are reasonable, they do involve assumptions,
risks and uncertainties, and these expectations may prove to be incorrect.
You should not place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors, including
the risk factors discussed in the Company's periodic reports that are filed
with the Securities and Exchange Commission and available on the SEC's
website ( http://www.sec.gov ). All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified in
their entirety by these risk factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
For more information, please contact:
Yongye Biotechnology International, Inc.
Mr. Larry Gilmore-VP of Corporate Strategy
Phone: +86-8232-8866 x8880
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
|SOURCE Yongye Biotechnology International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved